Renal denervation for uncontrolled hypertension Market Outlook 2026–2034: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines renal denervation, a catheter procedure that uses radiofrequency or ultrasound energy to quiet the nerves around the renal arteries and lower blood pressure in patients whose hypertension stays uncontrolled. It tests how far the procedure can grow from a first covered therapy to a routine option in hypertension care by 2034.

Payment has opened first. The Centers for Medicare and Medicaid Services issued a national coverage determination for renal denervation for uncontrolled hypertension in October 2025, covering both the radiofrequency system of Medtronic and the ultrasound system of Recor, with an implementation date of 6 April 2026. The conclusion is that coverage no longer depends on case by case decisions, which removes the largest barrier to hospital programmes.

Billing is the next step. The AMA CPT Editorial Panel has created two Category I codes for catheter-based renal nerve denervation, which take effect on 1 January 2028. The conclusion is that a permanent code set gives physicians a standard way to bill, and procedure volumes can build on it from 2028.

The effect on blood pressure is modest and the safety record is good. CMS described the reductions as comparable to those seen with a single antihypertensive medication and found the procedure safe with minimal impact on renal function. The conclusion is that renal denervation competes as an added option for patients who do not reach target on medicines, not as a replacement for drugs.

The brief treats renal denervation as an accelerating signal with an eight year horizon to 2034. It identifies which systems and companies move first and what each means for device makers, hospitals and payers. It is a focused 106-page decision brief that presents an indicative trajectory rather than a segmented market model.

The renal arteries carry the nerves that signal the kidneys to hold salt and raise blood pressure. Renal denervation delivers energy through a catheter placed in the renal arteries to reduce this signalling. The procedure is done once, and it is aimed at patients whose blood pressure stays high despite medicines.

Two approaches are approved in the United States. Medtronic Symplicity Spyral uses radiofrequency energy and Recor Paradise uses ultrasound, and the FDA approved both in November 2023. The conclusion is that two different energy sources are available to physicians, and competition is on delivery, evidence and support rather than a single technology.

Payment decides how fast use grows. Medicare covers both systems under a national coverage determination, and Medtronic states that private payers continue to offer coverage on an individual basis. Medtronic also lists new technology add-on payment and transitional pass-through payment for the Spyral catheter. The conclusion is that hospital payment is in place for Medicare patients, and commercial coverage is the next step.

The clinical case rests on a modest effect. CMS found that reductions in blood pressure were comparable to those from a single antihypertensive medication, with minimal impact on renal function. The conclusion is that the procedure fits patients who cannot tolerate or do not reach target with drugs, and adoption depends on how well referral pathways identify them.

The limits are the modest size of the effect, patient and anatomy selection, the number of trained operators and the lack of a commercial payer standard. The brief tests each limit against the cost trajectory to 2034.

The renal denervation market, covering radiofrequency and ultrasound renal denervation catheters, generators and procedure kits used to treat uncontrolled hypertension, and excluding antihypertensive drugs, blood pressure monitors and other device therapies for hypertension, is valued at USD 0.4–0.7 billion in 2026 and is projected to reach USD 2.88–5.04 billion by 2034, at a CAGR of 28%.

The 2026 base rests on radiofrequency and ultrasound renal denervation procedures billed mainly to Medicare and to commercial payers on an individual basis in the United States, with smaller sales in Europe and Asia. Growth then follows procedure codes, commercial coverage and referral from primary care.

The forecast is sensitive to commercial payer decisions, longer term blood pressure data and the pace at which centres train operators.

Scenarios.

The base case assumes commercial payers follow Medicare over the period after 2028, bringing the inflection to about 2029 and a 2034 value near the middle of the range. An accelerated case assumes strong long term blood pressure data and quick commercial coverage, bringing the inflection to 2027 and lifting the 2034 value to the top of the range. A delayed case assumes slow operator training and limited commercial coverage, moving the inflection to 2032 and holding growth at the bottom of the range.

Growth drivers

• Uncontrolled hypertension prevalence.
• Patients not reaching target on medicines.
• Outcomes against medical therapy.
• Wider patient groups.

Enablers

• Procedure planning.
• Smaller catheters and shorter procedures.
• Reimbursement and registry evidence.
• Hypertension referral programmes.

Restraints and barriers

• Anatomy and patient selection limits.
• Training and centre capacity.
• Modest blood pressure effect.
• Commercial payer coverage.

The direction of renal denervation is set by regulatory approvals, Medicare coverage, the size of the uncontrolled hypertension population, catheter and generator advances and the capacity of operators and centres.

The key participants in renal denervation include Medtronic plc, Otsuka Holdings Co., Ltd., Boston Scientific Corporation, Ablative Solutions, Inc., SyMap Medical (Suzhou) Ltd., Shanghai Golden Leaf MedTec Co., Ltd., Cardiosonic Ltd., Integer Holdings Corporation, Cirtec Medical Corp., Teleflex Incorporated, Abbott Laboratories, Terumo Corporation, Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Novartis AG, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Pfizer Inc., Bayer AG, Cleveland Clinic, Mayo Clinic, HCA Healthcare, Inc., Kaiser Foundation Health Plan, Inc., UnitedHealth Group Incorporated, Elevance Health, Inc., the American Heart Association, Inc., the American College of Cardiology, the European Society of Hypertension, the European Society of Cardiology, the Society for Cardiovascular Angiography and Interventions, the Cardiovascular Research Foundation, the Centers for Medicare & Medicaid Services, the American Medical Association and the Food and Drug Administration.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as coverage widens.

Medtronic and Otsuka lead with approved systems, Boston Scientific is entering through acquisition, and developers such as Ablative Solutions, SyMap Medical, Shanghai Golden Leaf MedTec and Cardiosonic add alternative approaches. Competitive intensity is moderate, with two approved systems in the United States and a small group of developers in trials.

Where value migrates.

In 2026 value sits with the two approved systems and the first covered procedures at centres with interventional teams. By 2029 it moves toward makers that support referral from primary care and win commercial coverage once procedure codes are in place. By 2034 it settles with renal denervation as a standard option, where long term blood pressure data, operator training and payer contracts carry the margin. Margins hold for makers with registries and payer relationships, and narrow for makers of single devices without coverage.

The signals converge on a market where approval and coverage are in place and billing codes are next. FDA approvals for two systems, a Medicare national coverage determination and permanent procedure codes support growth, while the modest blood pressure effect, operator training and commercial payer decisions hold back adoption.

Structural limits show where progress could slow: the number of trained operators, patient selection, the strength of long term blood pressure data and the pace of commercial coverage. The brief therefore tracks four indicators: procedures per year, centres with renal denervation programmes, commercial payer policies and long-term outcome data.

Medicare coverage first, then procedure codes and commercial payers, then standard option status is the expected order of change.